Novo Nordisk and Ypsomed Selfcare Solutions

Novo Nordisk, a pharmaceutical engild founded in Denmark in 1923, has been a pioneer of innovative insulin pitching methods for the treatment of diabetes with brand name calling Levomir® (an slam pen that uses a pre-filled, replaceable insulin cartridge) and AERx® (an insulin inhalant). While Novo Nordisk continues to be the world leader in diabetes treatment, the confederation has expanded into early(a) areas of enquiry and ontogenesis including human evolution hormone and astringent products in their biopharmaceuticals. Biopharmaceuticals is the method of developing products by biological exercise alternatively than chemical process frequently utilizing recombinant desoxyribonucleic acid, or DNA that is a combination of two or more organisms (Exploratorium, 2006). Ypsomed Selfcare Solutions, a keep caller-up based in Burgdorf, Switzerland, was launch in 2003 as a result of the split of the Burgdorf-based Disetronic Groups and is in addition involved in the medical appliances and equipment industry. Ypsomed is involved in the development and manufacture of custom-make injection pens and compatible pen needles for the boldness of self-injection solutions by patients (Ypsomed Selfcare Solutions, 2003-2006). The communitys products can lighten be used for a variety of applications and therapies such as insulin therapy, growth hormone therapy, and osteoporosis and inventory glucose monitoring. Ypsomed currently distributes its products primarily in Europe, but expect their mart to grow worldwide payable to the dramatic increase in diabetes cases.

PriceWaterhouseCoopers is the auditor of records for these two companies (Ypsomed yearly Report, 2005 and Novo Nordisk yearly Report, 2005). Novo Nordisk Financial Data-2005 Annual Report Novo Nordisk was the first Scandinavian company to be quoted on the sore York Stock Exchange, and is now an outside(a) company with representation in 69 countries (Wikipedia, 2005). The 2005 annual root states the company had a turnover of DKK 33.8 trillion, or approximately 4.5 billion EUR (X-rates, 2006). lend sales for diabetes products... If you want to beat out a unspoiled essay, ordinate it on our website: Orderessay

If you want to get a full information about our service, visit our page: How it works.